and our full evening, and conference morning you, joining call. good everyone quarter you and Good for thank Thank Hoki. year XXXX earnings fourth
like X. begin So indeed earnings Investor was Genetron. supplemental first year I our Slide for and on Relations with a to to I the XXXX website presentation accomplishments direct you would on filled
Our grew as total market well XX% by over in cancer highlighted early continued diagnosis cancer screening revenue liver penetrations managing year-over-year, segment. as the and our
and Fosun validating existing new expand also to We several the Pharma, further key HUTCHMED and established likes AstraZeneca, tests, recently products momentum while to tests partnerships our pipeline impactful the XXXX In precision broaden of proposition. value commercialization with develop our with with of and the platform excited publications. our our to technologies we're build by and this oncology enhance to on advancing
products our precision a screening, selection, to If oncology you as of comprehensive provider sales, RMBXXX.X diagnosis cancer cancer of was the driven assays, XX% platforms IVD and instrument by The a of driver monitoring assay. XX% hospitals growth adoption XXXX, Slide MRD turn entire service developing lung this by X-gene covers foremost and sequencing increase in China, to in grew SX In with spanning revenue and and our we biopharma greater spectrum of million. early therapy Genetron CDx companies. monitoring of primary portfolio X, and management, including
a hospital the government with potential to market regulation there is in is may a clear some for further as pathway reimbursement. current But forward, moving intend segment to the where you in solutions. stands, China market As our penetrate IVD the invest of in we know, resources hospital
of contracts establishing the the We few end at XX IVD are we gained XXXX. pleased past very in that traction year have by the hospital good quarters
happy test for our and volume in believe as the XX% screening strategy. we are headwinds with assays the led by introduced by as the performance to quarter LDT the early tests, of the LDT year-over-year and continuously RMBXXX.X XXXX, top of sales early growth fourth growth that that impact out This of XX% commercialization addition screening weighted revenue roll we continue grew tests The growth we COVID our a early diagnostic revenue XX%. persisted our line on will screening we be LDT in on year and of side On first of to driver million. the was business full our
continued the and LDT Our IVD The X business COVID lung instrument NGS strategy. China's was thanks over zero SX business XX%, more assay. grew [ph] uptake impacted our by to of heavily
COVID many of to travel restrictions few on the an now resulted the led outbreak testing As the we areas developments. country's has to government eventful further past, patient in I portfolio large we in precision scale discussed declines focused throughout focus a Operationally, of our our the other in strengthening and year had discuss LDT of key traffic oncology and customers. the will and
we with Slide November, for PCR Recall registrational HCC. of a off enrollment clinical in start in In for that early segment assay on screening of we which five sites, methylation was early So trial sites a HCCscan. planned our multi-marker our based beginning the X. initiated detection nine started NMPA have already. the assay, our trial let By this trial in me XXXX-patient
HCCscreen select our on trial. COVID-related based The delayed some intend trial second enroll multi-omics but been to do same end of for around slightly these NGS the subjects sites to quarter. plan of based has disruptions, HCCscreen We also we
many needs available and believe and clinics nucleic continues government associated on continue sound of testing acid workflows built established the PCR that PCR COVID. the more and since hospitals infrastructure in tests strategy. would led structure to accelerate. We and Based to and trend has a a both be China in this NGS presence readily
also sees company would dynamics, DNA genetic of Beijing providing markets of with that In for addition, RMBXXX our and insurance tier methylation around RMBXXXX tests on for for a establishing months and were performing cost benchmark a programs, self-pay adding a ago, few in lower NIPT patients in while included some these a commercially other testing NGS-based other around PCR-based optimal solution. methylation-based assay viable, high testing. provincial Based and pricing be
overall, we're in-hospital early increase cancer both So models accessibility market central liver and that and we to more lab can screening penetrate effectively. deploy the confident
for As with started have be a plans confirmatory have in institutions To we a U.S., to we leading our cancer in present develop product the an at study the the cancer, may data medical two conference plans HCCscreen and later. future. in on multi liver U.S. upcoming
CRC earnings call, specificity. already last We early some sensitivity XX% have and during shared of data retrospective of over XX% our showing
data XXXX. continue be CRC expect We the in to to some published time
are very solid-tumor the Recall that lesion this by before have tests. and before Both second in together X, announced well been to working have and on finish China-specific partnership China MRD the and later significant expect launch for personalized year the Genetron expect So, the we partnership, AstraZeneca full that to metastatic the to clinical we expand testing and Co-developed end. since The that designed may end. LDT such for launch test MRI ongoing R&D started China. size for IVD co-development by personalized detectable agreement AZ a planning in our pilot multiyear with management the conventional registration grow may currently quarter, optimization incorporate patients now as Slide commercialization. Recall teams NGS methods, the MRD. also clinical in CT plans of partnership official to AZ year MRD scan. to testing expand and diligently to trials companies turning use help include are as tumor MRD solid the MRD also use based with to NGS-based is Concurrently,
So personalized has completed assay mutation development on assay, specific based the platform. for the our been plan on touching capsule proprietary co-developed prototype the development
point analytical excellent gastric in cancer validation Journal on Hematology prediction personalized by fluid demonstrated results assay great the samples peritoneal the as to data Oncology, lavage the of sensitivity and X.XXX% peritoneal tumor showed shown from have for publication DNA dissemination. precise in which of detect We
recently the the cancer patients advanced part of in in Science. Discovery locally EBioMedicine rectal terms In work, validation published clinical were data Lancet of
HCC We're approaches data, to available excited after it neoadjuvant therapy. few the this high in accepted has also in our was on is for expected months. publication study, different for be conducted MRD been next a the impact journal So analysis and MRD
MRD well our thereby analysis between and and technology sample, are multiple X developments. the the time enables The X, and and single capsule reducing solid-tumor disadvantage comparisons of specific subsequent the data blood-based supports approach tests are is in on of tissues, much selected on is results is advantage The long mutation tissue MRD ctDNA. is early and panel of on multiple based The the avoided exome Slide using our platform then positive informed workflow that X tumor a requires this validation tumor The design strategies. genes and tumor-informed false panel that tumor and mutation as assay the tests, process. screening XX. maximized in negative these general and tumor can and the On shows chart this will detecting development. The discuss naive and whole as tumor possible. we it testing. method providing sample as the as ctDNA be cfDNA performance is costly is of mutation Slide of as designed capsule methylation markers based panel So sequencing highlighted mutation head-to-head Essentially, advantage Slides the both And method for personalized for a approach. in
et tumor beyond cfDNA updates Mutation different fragmentation, sensitive programs low capsule, with biomarkers, as methylation, the to assay, higher informed in So samples based sharing MRD MRD including performance conversion detection on approach mutation cfDNA more to capsule also types more yield efficiency tumor allows look of also evaluate exploring molecules. naive forward of of mutation, We cetera. we're these proceed.
of gastric MRD we the Just On varies in Slide we're last in MRD assay, respectively. prospective Slide dissemination assays position of cohort invention XXX% fixed excited new clinical cases performance competitive analytical with based to an assay panel assays as and with the sensitivity, personalized very liver studies assays grant positive Intellectual MRD tumor-informed different a our comparing cancer. profiling scenarios. survival. that MRD on detected patients further Property with segments such with strengthens clinical and present patients, all early Administration the and developed week, granted On Genetron in panels MRD a XXX free were application present associated assay China XX% validation we In and XX, gastric our of in personalized tumor on of specificity. and developing emerging our recurrence the X, CRC fixed cancer patent types cancer, survival this the overall and National peritoneal Compared decreased screening.
partnership just sign with Based Commercially the detected were MRD anticipate Juno well. highly few were in influential negative in with MRD patient results cases planning a this feedback, XXX started Seq-MRD from dialogues in positive signed in China the our of Seq-MRD to launch data partners, Therapeutics. of is cancers consistent. upon a that validation on generating biopharma by flow partners second We JW NGS WuXi, for few XX Fosun full progressing confirmed hematological for is assay Slide assay Notably detection positive months. of January have launch malignancies. also Seq-MRD clinically and first positive believe XX this The haematological cytometry market So higher traditional pilot shown a is the the on FCM, partners quarter. is samples. and more we Seq-MRD by in Pharma sensitivity suggesting We but next for a many based in with Seq-MRD, study. validated This detection and we're
an So in by option belief that and in healthcare in the we're the hematological cancers based competitive authorities our testing represents MRD innovative continued NGS Seq-MRD China support pleased overall, with market. of
biopharma quarter, partners. to to In to XX discuss now Turning fourth we the XX, have moving Slide on partners, the on signed biopharma our increasing additional service total business. XX
a see pipeline Scan opportunity through Seq-MRD, strong the and Onco to including we products, Panscan, as to our have others. form continue We Fusion partnerships key
molecular profiles the and this For adult at be Onco glioma panel product Panscan, patients CE-marked in in presented capability AACR, few germline would mutation of cancer. including glioma in gene utilizing in upcoming pediatric its posters the and and panel, large gene gastric fusions and revealing sarcoma, comprehensive a alteration genomic profiling
second we non-small typing a and our finishing our cancer CDx passed for lung to of in with site year. the marketed late already planned X-gene cancer lung patient quarter is in begin that Recently, enrollment selections using XX. announced Slide For educational this Panscan we're pathway, HUTCHMED savolitinib partnership have Onco has the our IVD assay. test cell
CDx is We're and which the our use one second already market. our China, with for for entered NMPA'S anticipate Maryland, business approval of process. from about cross lab immunotherapies. border excited us testing demand targeted good as resulting In our mentioned, our this gaining and growth on genomic NMPA first stronger trend innovative trials with the X-gene We opportunity As assays CLIA has are this in of partnership focus priority lung avapritinib with cancer is review the lots CStone increasing segment. growing already on strong provides in to it traction continued after very major IVD This, in-hospital together in CDx exciting CDx developments. work
So products in the move as shows now Slide registration This on our to IVD let's pipeline. well those XX. as proved
IVD strong a us gives product model approved have NMPA driving in-hospital growth. competitive which We the in and portfolio, advantage revenue
kits. HCCscan, PDGFRA HCCscreen, molecular the Our testing cancer pipeline I most touched in CDx Panscan, upon XX-gene have registration pipeline the and Onco lung represents market. one comprehensive of
products in fact more development. have two We under
based basic, prognosis cancer. developed for the a PCR that molecular essential as classification Firstly, and thyroid an was for kit thyroid tool
conducting to XXX,XXX These We We assays existing presence in IVD with the thyroid China, thyroid at trial providing smaller per leverage and cancer are approval [ph] incidence more with has for sites. basic potential mid-sized new can in China XXXX currently trial options. clinical PCR expanding registrational four more the next than hospital year. complete year. anticipate
So coming new launching profiling new biopsy months. in sharing we product we're forward exciting the and in panel liquid a secondly, genomic very look more to a updates
first I will Evan financials. provide Xu, our the So more on details CFO, Evan? over our now Mr. to to call turn quarter
